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Abstract 
The capability of human pluripotent stem cell (hPSC) lines to propagate 
indefinitely and differentiate into derivatives of three embryonic germ layers 
makes these cells be powerful tools for basic scientific research and promising 
agents for translational medicine. However, variations in differentiation 
tendency and efficiency as well as pluripotency maintenance necessitate the 
selection of hPSC lines for the intended applications to save time and cost. To 
screen the qualified cell lines and exclude problematic cell lines, their 
pluripotency must be confirmed initially by traditional methods such as 
teratoma formation or by high-throughput gene expression profiling assay. 
Additionally, their differentiation potential, particularly the lineage-specific 
differentiation propensities of hPSC lines, should be predicted in an early 
stage. As a complement to the teratoma assay, RNA sequencing data provide 
a quantitative estimate of the differentiation ability of hPSCs in vivo. Moreover, 
multiple scorecards have been developed based on selected gene sets for 
predicting the differentiation potential into three germ layers or the desired 
cell type many days before terminal differentiation. For clinical application of 
hPSCs, the malignant potential of the cells must also be evaluated. A 
combination of histologic examination of teratoma with quantitation of gene 
expression data derived from teratoma tissue provides safety-related 
predictive information by detecting immature teratomas, malignancy marker 
expression, and other parameters. Although various prediction methods are 
available, distinct limitations remain such as the discordance of results 
between different assays and requirement of a long time and high labor and 
cost, restricting their wide applications in routine studies. Therefore, simpler 
and more rapid detection assays with high specificity and sensitivity that can 
be used to monitor the status of hPSCs at any time and fewer targeted 
markers that are more specific for a given desired cell type are urgently 
needed. 
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Core tip: To save time and costs in basic research and clinical application, it is 
necessary to predict the differentiation potential of human pluripotent stem 
cell (hPSC) lines. Multiple methods are available for pluripotency screening, 
lineage-specific differentiation propensity prediction, and malignancy 
potential detection, which can be used to select hPSCs. However, simpler and 
quicker methods using fewer specific targeted markers for the desired cell 
type are urgently required for routine work. 
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INTRODUCTION 
The capability of human pluripotent stem cells (hPSCs) to differentiate into 
any cell type has revolutionized medical research. Their widely known 
potential applications include the study of complex diseases, cell-based drug 
screening, and transplantation therapy[1]. With the development of organoid 
technology, hPSCs also play a critical role to mimic in vivo tissues and organs 
at the three-dimensional level and provide a unique opportunity to model 
human organ development and study various diseases[2]. In the near future, 
integration of multiple patient-specific hPSC-derived organoids into a 
dynamic four-dimensional system by organ-on-chip technology will 
contribute to the study of the systematic interactions among different tissues 
and organs in the body[3]. All these applications require the selection and 
characterization of cell lines that reliably, efficiently, and stably differentiate 
into disease-relevant cell types. However, significant variation has been 
observed in the differentiation potential and efficiency of various human 
induced pluripotent stem cell (iPSC) lines[1,4,5] and embryonic stem cells 
(ESCs)[6-8], and no single cell line can uniformly differentiate into all lineages. 
Differences among hPSC lines mainly include DNA methylation[9-13] and gene 
expression[1,8], which have functional implications for both ESC and iPSC 
lines[1]. Particularly, for iPSCs, the variations may be donor-dependent[14,15] or 
original cell type-dependent[9], while, in other studies, this relationship was 
not found[10,16]. Moreover, the characteristics of hPSCs may differ depending 
on the number of passages[17], culture medium components[18], and feeder 
conditions[19]. As a result, understanding the variability among different cell 
lines is necessary for ensuring the efficacy and safety of hPSC applications. 
Additionally, a long period (up to weeks or months) is typically required to 
complete hPSC differentiation into a specific cell type, and protocol 
optimization to improve differentiation efficiency is also time-consuming. 
Thus, these processes can be considerably accelerated if good-quality hPSC 
lines are selected, and their differentiation propensities into destination cell 
types are predicted in an early stage. 
 
hPSC quality control  
Given that large numbers of iPSC lines are currently and will be generated, 
the pluripotency of these cells must be determined before they are broadly 
applied. To confirm whether an iPSC line is fully reprogrammed, a teratoma 
assay is typically performed to reveal the differentiation capacity of hPSCs 
into three germ layers based on histological analysis. The pluripotency status 
can also be determined by detecting the expression of a set of marker genes at 
the molecular level[20]. With the development of high-throughput sequencing 
techniques, numerous methods have been developed to address this issue. 
The PluriTest®[21], a rapid test based on microarray and bioinformatics assay, 
provides quantitative information on hPSC quality. Two summary scores, the 
pluripotency score and novelty score[22,23], which are generated from global 
gene expression profiles, can predict whether an hPSC line is pluripotent 
based on its molecular similarity to other known cell lines and exclude cells 
that differ substantially from normal hPSC lines. An hPSC line with a high 
pluripotency score and low novelty score would be regarded as having 
passed the PluriTest. Another assay, the “deviation scorecard”[1], which 
combines DNA methylation and gene expression with bioinformatic 
comparison to an ESC reference, also provides comprehensive information 
and excludes problematic cell lines that should be avoided for an intended 
application. However, these methods can only be used to determine whether 
an hPSC line meets the criteria for pluripotency and do not directly assess the 
specific differentiation capability of the cells. 
 
Prediction of differentiation potential 
As described above, the teratoma assay is the most frequently used method to 
assess the pluripotency of hPSCs. However, it does not yield quantitative 
information on lineage differentiation potential[24] nor provide specificity data 
to support the application-specific selection of the most suitable cell lines[25]. 
Thus, the “TeratoScore” was developed[26] as a quantitative and unified 
assessment that analyzes RNA sequencing data within heterogeneous 
hPSC-derived teratomas. This score weighs differences in tissue-specific 
expression within a teratoma and provides an estimate of the ability of an 
hPSC line to differentiate[22,23,26] to overcome some of the limitations of 
histological analysis. 
hPSC differentiation is a complex and multiple-step process, the beginning 
of which involves a particularly heterogeneous status and diverse 
developmental mixture. During cell fate commitment to a differentiated 
lineage, genes are regulated by successive transcriptional programs, and thus, 
the differentiation status can be determined from transcriptional profiles[27]. A 
combination of gene expression profiling and bioinformatics assay is 
invaluable for predicting the trajectory of cells during differentiation. The 
“differentiation scale”[27] based on mRNA microarray analysis can indicate the 
staging of differentiation and show how far the hPSCs have departed from 
the embryonic pluripotent state. However, this method only measures the 
overall capability of a cell line towards differentiation into any cell type and 
cannot clearly distinguish between any direction of differentiation into the 
three germ layers. In contrast, the “lineage scorecard” assay, which combines 
simple nondirected differentiation with transcript counting of 500 lineage 
marker genes, can detect the lineage-specific differentiation propensities of an 
hPSC line[1]. For example, hPSC lines showing high scores for ectoderm and 
neural differentiation propensities are regarded as well-suited for studying 
neural function. This prediction has been confirmed in experiments to 
quantify differentiation efficiencies specific for the ectoderm germ layer. 
Additionally, other scores calculated based on the expression levels of a set of 
selected specific gene markers can predict hPSC differentiation potential in 
similar manners[22,23,28]. These qPCR-based assays are more rapid and 
accessible than high-throughput methods.  
According to the hPSC-derived differentiation protocols for various types 
of cells, embryoid bodies (EBs) are widely used[29] because they mimic many 
aspects of cell differentiation during early embryogenesis. Because they 
consist of tissues containing three germ layers[30], EBs can be utilized as a 
trigger of not only in vitro differentiation of hPSCs but also in assay predicting 
differentiation potential. For the latter purpose, EBs are induced to 
spontaneously differentiate under neutral conditions[1,22] or directed into three 
germ layer lineages in the presence of specific growth factors[22,28], after which 
gene expression profiling of EBs is conducted to assess their differentiation 
potential into the ectoderm, mesoderm, or endoderm lineages. In our study to 
predict the differentiation potential of iPSCs into melanocytes derived from 
the ectoderm, an EB-based assay showed that this potential could be 
predicted by the capability of formation and maintenance of optimal EBs 
under neutral conditions as well as their expression of germ layer-specific 
markers such as SALL3 (our unpublished data). Thus, EBs are practical tools 
for use in prediction assays at early stages of differentiation. In addition to 
EB-based protocols, monolayer differentiation[23,31] has been adapted and 
shown to be applicable for evaluating endoderm and mesoderm direction; 
however, to predict the ectodermal direction, EB-based protocols may be 
more effective[23].  
Regardless of the detection techniques used, prediction can be achieved 
many days before the cells exhibit a differentiated phenotype (Table 1). For 
instance, the efficiency of protocols for directing differentiation to cardiac cells 
can be predicted at as early as day 2[31], and thus can be utilized to optimize 
differentiation protocols, particularly for patient-specific iPSC lines by using a 
high-throughput screening procedure. In contrast to the above methods based 
on EBs or monolayer differentiation protocols, which require a couple of days 
before evaluation, simpler methods with limited specific markers can be used 
for earlier prediction using undifferentiated hPSCs. The expression level of 
SALL3 mRNA was used as a diagnostic marker to predict the differentiation 
tendency of both iPSCs and ESCs into ectodermal cells[32]. hPSCs expressing 
the highest levels of SALL3 mRNA tend to differentiate into the most 
ectodermal system, while cells expressing the lowest levels of SALL3 mRNA 
tend to differentiate into the most mesodermal or endodermal cell types. 
Specifically, three genes, FGF-1, RHOU, and TYMP, were selected as 
predictors of hepatic differentiation, with low prediction scores linked to low 
hepatic differentiation[33].  
Collectively, the lineage-specific differentiation potential of hPSC lines can 
be predicted in an early stage using multiple assays, including the teratoma 
assay, different scorecards calculated by high-throughput sequencing data 
collected from EBs or monolayer-based differentiated hPSCs, or specific 
maker expression in undifferentiated hPSCs. 
 
Evaluation of malignancy potential 
The safety of using hPSCs in clinical application is one of the greatest 
concerns for both clinicians and patients[34]. Currently, tumorigenicity tests 
are well-designed, and animal transplantation studies have been used to 
detect the malignancy potential of hPSC-derived cell products[35,36]. Although 
residual undifferentiated cells are present among the differentiated cell 
population, these cells can be ablated by various techniques[37,38]. Additionally, 
evaluation of hPSCs rather than their derivatives can provide safety-related 
information. As described above, the teratoma assay is commonly used to 
measure the pluripotency and differentiation potential of hPSCs[22,39]. It is also 
feasible to predict the malignancy potential by detecting the immaturity of 
teratomas and formation of carcinoma or sarcoma in tumors derived from 
hPSC lines[40]. Furthermore, a combination of histologic examination and 
“TeratoScore”, which involves computational quantification of gene 
expression data derived from teratoma tissue, can provide much greater 
detail for evaluating whether a cell line has the malignant potential[22,23]. It is 
also important to examine chromosomal abnormalities by karyotype 
analysis[40,41] and assess mutations in cancer-related genes[40]. 
 
LIMITATIONS AND CHALLENGES 
Collectively, multiple screening tools are available for hPSC selection with 
different features and prediction capabilities, and researchers can choose one 
or more methods according to the intended applications (Table 1 and Figure 
1). However, concordance between two different prediction methods is 
low[22,23], and even with the same prediction assay, distinct results may be 
obtained under different differentiation conditions. The lack of concordance 
of results makes it very difficult for researches to determine the most 
appropriate method for their purposes. Moreover, each prediction method 
has limitations, thus largely restricting its wide applications. 
High-throughput analysis methods such as microarray or RNA-sequencing 
are informative but generate excessive data, some of which are non-functional. 
Additionally, identifying objective genes is time- and labor-intensive as well 
as costly[33]. The platforms used in these assays are not available to most 
laboratories and require customized downstream analysis, which also 
restricts their applications. Although teratoma formation reflects the in vivo 
differentiation capability of hPSCs and gene expression analysis can provide 
more definitive and quantitative information when combined with 
histological assessment, these methods are also very time-consuming to be 
feasible for validating a large number of hPSC lines[1]. 
Because of these limitations, the methods described above are not sufficient 
to meet the needs of researchers in routine work. Additionally, hPSC 
characteristics are not stable during long-term culture, which can be affected 
by several factors. Further, hPSCs can vary when they are cultured using 
different commercial products or show different features in different 
laboratories, even under the same culture conditions. Therefore, a simpler and 
quicker detection assay with high specificity and sensitivity that can be used 
to monitor the status of hPSCs at any time is needed. Although most current 
methods are useful for lineage-direction prediction, fewer targeted markers 
that are more specific for a given cell type rather than all cell types are 
urgently needed. Moreover, EBs are ideal candidates for replacing the 
teratoma assay, and they should be useful for predicting differentiation 
potential when they are combined with modified detection methods such 
molecular probes, which could detect targeted markers directly.  
Exceptionally, the potential prediction is not a prerequisite when iPSCs 
from patients with monogenic disease are utilized for disease modeling 
because the differentiation capability is probably interfered by gene 
mutation[42]. However, iPSC quality control is still necessary. When using 
these patient-derived iPSCs for cell therapy, it is also critical to predict their 
differentiation potential after some special strategies such as gene editing, 
which can revert their defective capability.  
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Figure 1 Schematic flow diagram of quality control of human pluripotent 
stem cells. hPSCs: Human pluripotent stem cells.  
Table 1 Methods for evaluating human pluripotent stem cell lines for pluripotency, differentiation potential, and malignant 
potential 
Aim Techniques Targets Cell 
treatment 
Timepoint 
detection 
Ref. 
 
 
 
Pluripotency 
DNA methylation 
sequencing and 
microarray 
Deviation scorecard: the cell line-specific number of 
outliers relative to the human ES cell reference 
N/A 
 
N/A 
 
[1] 
Microarray PluriTest: pluripotency score (refers to gene expression 
profiles of a large collection of human PSCs) and 
novelty score (refers to gene expression patterns not 
typically associated with human PSCs) 
N/A N/A [21-23] 
qPCR Level of CHD7 N/A N/A [43] 
 
 
 
 
 
 
Microarray Differentiation scale: a subset of the 1000 most 
informative genes 
W/O At any 
time of 
differentiat
ion 
[27] 
Microarray Lineage scorecard: 500 lineage marker genes to 
monitor cell state, pluripotency, and differentiation 
Nondirecte
d EB 
 
At 16 d of 
[1] 
  
 
 
 
 
Differentiatio
n potential 
 
differentiat
ion  
differentiat
ion 
 qPCR Lineage scorecard: 15 selected marker genes per 
lineage  
Nondirecte
d and 
directed 
differentiat
ion into 
three germ 
lineages 
[22] 
qPCR hPSC ScoreCard: 9 self-renewal genes and 70 genes 
representing specific lineages 
Monolayer 
or EB 
protocol 
differentiat
ion into 
three germ 
lineages 
At 5 or 9 d [23] 
Single-cell qPCR 96 developmental genes; a transcriptional circuit 
(HAND1-SOX17) and phenotypic readout (cKIT 
Cardiomy
ocyte 
On day 2 [31] 
distribution) differentiat
ion 
qPCR Improved scorecard: 96 specific gene markers Directed 
EB 
differentiat
ion into 
three germ 
lineages 
At 12 d of 
differentiat
ion. 
[28] 
Microarray or 
RNA-sequencing 
TeratoScore: 100 tissue-specific genes representing the 
three embryonic germ layers and extra- embryonic 
membranes 
Xenograft 
teratoma 
formation 
A suitable 
growth 
period 
[22,23,
26] 
Morphology Definitive endoderm morphology production Treated 
with small 
molecules 
48 h after 
induction 
[44] 
qPCR SALL3 for ectodermal differentiation N/A N/A [32] 
PCR array Prediction scores for hepatic differentiation based on 
the expression of the three genes FGF-1, RHOU, and 
TYMP 
N/A N/A [33] 
  
 
Malignant 
potential 
Histology, qPCR, 
and microarray 
TeratoScore: 10 undifferentiated hPSC markers; 
embryonal carcinoma-like cells with yolk sac elements; 
undifferentiated hPSC marker and malignancy marker 
expression 
Xenograft 
teratoma 
formation 
 
Suitable 
growth 
period 
[22]  
TeratoScore: 100 tissue-specific genes; embryonal 
carcinoma-like cells; undifferentiated hPSC marker 
and malignancy marker expression 
[23] 
Histology, 
microarray, 
karyotype 
analysis, and 
whole exome 
sequencing 
Formation of immature teratomas, carcinoma and 
sarcoma; mutation of cancer-related genes; 
chromosomal abnormalities 
Xenograft 
teratoma 
formation; 
N/A 
Suitable 
growth 
period; 
N/A 
[40] 
hPSCs: Human pluripotent stem cells; N/A: Not available.  
 
 
